INTRODUCTION
The identification of citrullination has been a major milestone in the study of rheumatoid arthritis (RA) (1, 2) . Citrullination is the posttranslational modification of arginine residues to citrulline in proteins, catalyzed by peptidyl arginine deiminase (PAD) enzymes, as one of the key factors mediating the breach in tolerance and eliciting anti-citrullinated protein antibody (ACPA) responses. The appearance of ACPAs in the circulation precedes the onset of clinical disease, and ACPA positivity has a sensitivity of 60-70%, and a specificity of >90%, for the diagnosis of RA (1) . ACPAs have been shown to trigger human immune effector functions, including activation of the complement system and the ability to engage activating Fcγ receptors (3) . In addition, it has been demonstrated that ACPAs can catalyze the bone erosion commonly seen in RA patients (4) .
Although the indispensable role of B cells in autoantibody production is well recognized, their autoantibody-independent contributions are not as well-defined. Systemic depletion of B cells using rituximab, a strategy that targets B cells expressing human CD20 (a phenotypic cell surface marker), has been shown to be effective clinically for the treatment of a subset of RA patients (5) . Although studies have supported the idea that patients with higher autoantibody titers are likely to respond to rituximab (6) , the clinical efficacy of rituximab treatment is not necessarily correlated with a decrease in autoantibody titers (7) . This, in turn, implies a more expanded role for B cells in autoimmune pathogenicity beyond antibody production.
Preclinical and clinical data have suggested many different functions of B cells in RA, including 1) a role as antigenpresenting cells (8) , 2) direct secretion of proinflammatory cytokines, such as tumor necrosis factor (TNF) and interleukin-6 (IL-6) (9) (10) (11) , that support the organization of tertiary lymphoid tissues within the inflamed synovium (8, 12) , and 3) an effect on bone homeostasis through the secretion of RANKL (13) . Despite these efforts, a direct interrogation of the roles of the autoreactive B cell compartment, and how they differ from other B cells from the same donor or from B cells from healthy individuals, has not been accomplished.
One of the major challenges in profiling autoreactive B cells within humans is the low frequency of these cells in peripheral blood (<0.1% of all B cells in the circulation) (14) . We developed and validated a flow cytometry-based assay for the reliable detection of cyclic citrullinated peptide (CCP)-specific B cells ex vivo. We then performed RNA-sequencing (RNA-seq) on these small numbers of cells with the purpose of comparing the whole transcriptome profile of RA-CCP-specific (RA-CCP POS ) B cells to that of RA-CCP-negative (RA-CCP NEG ) B cells from the same donor and to that of hemagglutinin-specific (HA POS ) B cells from healthy individuals elicited upon vaccination with seasonal influenza virus. We performed a 2-pronged comparison to identify the expression of key genes on all B cells from RA patients that were presumably induced by the systemic proinflammatory environment prevailing in these patients, as well as those genes that were restricted to only autoreactive B cells.
Our data identified a novel role of B cells as an activator of the epidermal growth factor (EGF) pathways by secretion of the EGF receptor ligand amphiregulin (AREG) under proinflammatory conditions, and also identified IL-15 receptor α (IL-15Rα) as a specific biomarker of RA-CCP POS B cells. Overall, our data suggest that besides being a source of autoantibodies, B cells may also play direct roles in the inflammatory cascades and osteoclastogenesis in RA. Significantly, while some of the identified genes and pathways are the targets of approved therapies for RA, our data also illustrate that drugs approved for other indications might be useful in targeting the RA-CCP POS B cell compartment in RA. More broadly, to the best of our knowledge, this is the first comprehensive study on the transcriptome profile of human RA-CCP POS B cells in any autoimmune disease, and these data could serve as a resource to further investigate the role of B cells in autoimmunity.
MATERIALS AND METHODS
Patients. Blood samples were obtained from patients with seropositive RA who provided informed consent for study participation under Institutional Review Board-approved protocols at the Baylor College of Medicine, University of Alabama at Birmingham, and University of Houston. Each blood sample (15 ml) was aspirated into heparin vacutainer tubes (BD Biosciences). Details on the patients' demographic and clinical characteristics are summarized in Supplementary (15) , and all were confirmed to be CCPseropositive.
Flow cytometric sorting of CCP-specific B cells from RA patients' blood. Peripheral blood mononuclear cells (PBMCs), isolated from the blood of RA patients by density centrifugation, were blocked with phosphate buffered saline (PBS)-5% human serum for 20 minutes at 4°C. All subsequent staining steps were performed in PBS containing 2% serum. PBMCs were stained for B cell markers with fluorochrome-labeled antibodies, anti-CD19, IgM, and IgD together with a T cell marker using an anti-CD3 antibody (BioLegend) according to the manufacturer's instructions. Biotinylated CCP-I (Anaspec), a surrogate peptide to capture ACPAs, was then added (1 μg/million PBMCs), followed by labeling with fluorochrome-labeled streptavidin (1 μg/ml). Subsequently, biotinylated cyclic arginine peptide (CAP; Anaspec) was also added (1 μg/million PBMCs) as a control, and then labeled with fluorochrome-labeled streptavidin ( /well of 3T3 fibroblast cells secreting msCD40L (NIH AIDS reagent program), 100 ng/ml of IL-21 (PeproTech), and 5 μg/ml of anti-APO-1 antibody (eBiosciences) for a period of 14 days, with half of the medium changed once after 7 days. Thereafter, cell purity was assessed by validating the specificity of IgG from the culture supernatants against CCP.
Preparation of the complementary DNA (cDNA) library and RNA-sequencing analyses. Total RNA was obtained by sorting antigen-specific B cells (350-1,000 total cells) ex vivo directly into 100 μl of cell lysis buffer, provided in the RNA-XS RNA isolation kit (Macherey-Nagel). Furthermore, cDNA libraries were synthesized using the commercially available | 531 SMART-Seq Ultra Low Input RNA kit (Clontech), in accordance with the manufacturer's protocols. After preparation of cDNA libraries, they were first tagmented and then barcoded by indexing primers using the Nextra XT kit (Illumina). The libraries were pooled and a 76-bp paired-end sequencing was performed on an Illumina HiSeq3000 sequencer, to yield a minimum of 17 Tables 3 and 4) . We evaluated the statistical power of our study to differentiate the RA-CCP POS and RA-CCP NEG B cell subsets. Using powsimR (17), we estimated the statistical power of our study to be 0.86 ± 0.18 (mean ± SEM based on 100 simulations).
Comparisons between RA-CCP POS and HA POS B cells.
A number of candidate DEGs whose presence has been well validated in studies of autoimmunity, including the cyclin kinase p21 (CDKN1A) (18) , ubiquitin ligase PelI1 (19) , and costimulatory molecule ICOSLG (20) genes, were identified. The EGF ligand gene AREG was identified as the transcript with the largest change in expression ( Figure 2B ). By classifying these same DEGs into Gene Ontology categories, we grouped them as being related to B cell activation, genes related to inflammation, and transcription factors. We observed differences in the expression of genes related to B cell activation ( Figure 2C ), with increased expression of kinase genes such as PI3KCA (21) and MAPK7/MAPK8, which are known to cause autoimmunity under dysregulated activation (22) . In addition, several genes related to inflammation, including signaling molecules such as TNFAIP3 and IL6ST and T cell-recruiting chemokine-like CCL5 and the chemokine receptor gene CXCR4 (23, 24) , were up-regulated in RA-CCP POS B cells ( Figure 2D ).
Analysis of the differentially expressed transcription factors revealed up-regulation of PRDM1 and ETV3 and ETV3L within RA-CCP POS B cells; these transcription factors are known to inhibit c-Myc and, consequently, hinder cell growth (25) , while at the same time they can promote B cell differentiation and Ig secretion (26) . Similarly, the small macrophage-activating factor family of transcription factors (MAFF and MAFG), which have a direct impact on Ig secretion (27) , were enriched in these RA-CCP POS B cells ( Figure 2E ).
We also sought to determine whether there was a B cellspecific change in expression of genes known to be high-risk loci in RA, as has been documented through large-scale genetic studies (28) . Of the known RA-specific loci, 9 genes were also identi- POS B cells were plotted with the enrichment map application in Cytoscape, using a cutoff false discovery rate (FDR) q value of 0.01 and P value of 0.005. Nodes (red and blue circles) represent pathways, and the edges (green lines) represent overlapping genes among pathways. The size of nodes represents the number of genes enriched within the pathway, and the thickness of edges represents the number of overlapping genes. The color of nodes was adjusted to an FDR q value ranging from 0 to 0.01. Clusters of pathways are labeled as groups with a similar theme. All pathways represented are enriched in RA-CCP POS B cell populations. TNFR1 = tumor necrosis factor receptor 1; PI3K = phosphatidylinositol 3-kinase; IL-17A = interleukin-17A; LPS = lipopolysaccharide; NGF = nerve growth factor; ICOS = inducible costimulator; IRF = interferon regulatory factor; FcγRIIb = Fcγ receptor type IIb; HIF1a = hypoxia-inducible factor 1α; ILK = integrinlinked kinase; TGFβ = transforming growth factor β; HMGB1 = high mobility group box chromosomal protein 1; mTOR = mechanistic target of rapamycin; AMPK = AMP-activated protein kinase; IGF-1 = insulin-like growth factor 1; BMP = bone morphogenetic protein; Gαq = G protein-coupled receptor; PDGFRB = platelet-derived growth factor β receptor; EGFR = endothelial growth factor receptor; TLR = Toll-like receptor; IFNγ = interferon-γ; TAK1 = TGFβ-activated kinase 1; NRG1 = neuregulin 1; TRAF6 = TNFR-associated factor 6; MyD88 = myeloid differentiation factor 88; MHC-I = class I major histocompatibility complex; BCR = B cell receptor; ER = endoplasmic reticulum (see Figure 1 for other definitions). (Figures 2F and G) , which recognizes pathogen-associated molecular patterns, and its binding partner in the complement cascade, C1QB (29, 30) , bone morphogenetic protein genes BMP2 and BMP5, and PAD citrullinating enzyme genes PADI2 and PADI6 (31) ( Figure 2F ). In addition, several immune-related transcripts, such as inflammasome-associated protein gene NLRP7 ( The pathways in group 1 were B cell activation pathways (B cell receptor signaling, phosphatidylinositol 3-kinase/AKT, and p38 MAPK), Toll-like receptor (TLR)-based activation pathways (TLR signaling and lipopolysaccharide-stimulated MAPK pathways), and TNF superfamily ligand-mediated signaling pathways (CD40, APRIL signaling) and their receptor signaling pathways (TNFR1, TNFR2, CD27, RANK, and CD40). The pathways in group 2 comprised inflammatory cytokine signaling (IL-6, IL-8, and IL-17A) and RAspecific signatures (role of macrophages, endothelial cells, and osteoclasts in RA), as well as pathways of B cell activation/homeostasis (PTEN, NF-κB, and NFAT activation) and function (phagosome maturation, FcγRIIb signaling, and antigen presentation). Finally, group 3 showed enrichment in pathways for protein citrullination, G protein-coupled receptor (Gαq) signaling and cyclic AMP signaling ( Figure 3A) . Overall, whereas TNF signaling (group 1) has a global impact on all B cells from RA patients, these data suggest that RA- indicating that IL-15Rα expression was significantly enriched in this population ( Figure 4E ). Since IL-15Rα can also be converted to the soluble form by proteolytic cleavage via the TNFα-converting enzyme (TACE) (34), we next investigated the concentrations of soluble IL-15Rα (sIL-15Rα) in the RA patient cohort. Although elevated concentrations of sIL-15Rα in the synovium are known to be associated with increased disease activity, there are no known reports that have documented elevated sIL-15Rα concentrations in the serum of seropositive RA patients (35) . To systematically validate a large number of candidate proteins within the RA patients' sera, including sIL-15Rα, we took advantage of the aptamerbased SOMAscan assay, which can detect analytes at picomolar concentrations by utilizing very small volumes of biologic samples (36) (as depicted in Supplementary Figure 6 , http:// onlinelibrary.wiley.com/doi/10.1002/art.40772/abstract). In a cohort of CCP-seropositive RA patients (11 samples) compared to healthy donors (10 samples), we observed significantly higher concentrations of both IL-6 and IL-8 in the RA patients, but no differences were seen in the concentrations of a large panel of other soluble analytes, including IL-1β or IL-17 (see Supplementary Figure 7 , http://onlinelibrary.wiley.com/doi/10.1002/ art.40772/abstract). When we evaluated sIL-15Rα, we observed significantly higher concentrations in the sera of RA patients in comparison to healthy controls ( Figure 4F) .
Finally, we also looked at the predictive value of serum sIL-15Rα for the occurrence of CCP-seropositive RA, as determined by the SOMAscan assay, and found that sIL-15Rα displayed both high sensitivity and high specificity for RA compared to healthy controls ( Figure 4G ). Using pROC, we confirmed the statistical power of sIL-15Rα in this independent cohort of CCPseropositive RA patients, which yielded a power estimate of 0.88.
EGFR pathways and molecular validation of AREG in
RA B cells. AREG is a member of the EGF family of ligands that signal through the EGFRs. It has been previously documented that TNF signaling in conjunction with IL-1β signaling can lead to the up-regulation of AREG (34, 37) . Our data support a pivotal role of AREG in RA-CCP POS B cells ( Figure 5A ), and also a role of its downstream target pathway, EGF-mediated signaling ( Figure 5B ). In order to validate our findings, we used flow cytometry to directly interrogate the expression of AREG within individual B cells from an independent cohort of seropositive RA patients. As expected, we did not observe expression of AREG on RA-CCP Elevated expression of AREG in the serum and synovial fluid of RA patients. Among the different EGF ligands that are known to induce proliferation, growth, and differentiation by signaling through the EGFRs (39), AREG plays a unique role in its ability to induce both cell proliferation and cellular differentiation upon receptor binding (40) . Although serum AREG levels in RA have been documented in other reports, these data are contradictory (41) (42) (43) . We evaluated the concentrations of AREG and the other EGF ligands in the serum of CCP-seropositive RA patients, using the SOMAscan array as outlined above. In this cohort, we observed a significantly higher concentration of . D, Serum concentrations of AREG were determined in RA patients (n = 11) and healthy individuals (n = 10) by SOMAscan aptamer assay. The statistical power of this assay was estimated to be 0.98. E, Serum concentrations of all other EGF ligands in RA patients and healthy controls were identified by SOMAscan. F, Synovial fluid was assessed for AREG expression by enzyme-linked immunosorbent assay in patients with RA (n = 21) compared to patients with osteoarthritis (OA). In A and D-F, horizontal lines with bars show the mean ± SEM. ** = P < 0.01; *** = P < 0.001, by Mann-Whitney U test. NES = normalized enrichment score; FDR = false discovery rate; HBEGF = heparin-binding EGF-like growth factor; BTC = betacellulin (see Figure 1 for other definitions). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40772/abstract. AREG in the serum of RA patients ( Figure 5D ), but no differences were seen in the concentrations of any of the other EGF ligands investigated, such as heparin-binding EGF-like growth factor, betacellulin, epiregulin, EGF, and neuregulin ( Figure 5E ).
In addition, we observed a high sensitivity and high specificity of serum AREG in predicting the occurrence of RA (see Supplementary Figure 9 , http://onlinelibrary.wiley.com/ doi/10.1002/art.40772/abstract). The estimated statistical power of serum AREG concentrations for prediction of RA in our cohort was 0.98.
Since RA is a disease with localized inflammation, we further evaluated the abundance of AREG in the synovial fluid from CCP-seropositive RA patients (21 samples) and compared it with synovial fluid samples from patients with noninflammatory osteoarthritis (OA) (8 samples). Our ELISA results showed that the levels of AREG were significantly higher in RA synovial fluid compared to OA synovial fluid (only 1 OA synovial fluid sample tested positive for AREG) ( Figure 5F ).
Promotion of migration and proliferation of FLS in vitro by AREG.
One of the hallmarks of RA pathogenesis is the activation of FLS, which is characterized by a tumorlike aggressive phenotype within the joints (44) . We tested the ability of AREG to increase the invasiveness of human RA FLS, Results are the mean ± SEM. * = P < 0.05; ** = P < 0.01; *** = P < 0.001 versus control, by two-way analysis of variance. C, Expression of epidermal growth factor receptor (EGFR) on RA FLS is shown (n = 3 replicates). The light gray line represents unstained cells. D, Proliferation of FLS was measured using 5,6-carboxyfluorescein succinimidyl ester (CFSE) dilution (n = 3 replicates). E, Enrichment of ACPAs against cyclic citrullinated peptide (CCP) in the plasma of 2 RA patients was assessed by enyzme-linked immunosorbent assay (n = 2 replicates). F and G, Representative examples of differentiation of osteoclasts from blood monocytes under 2 different conditions are shown. Arrows indicate differentiated osteoclasts with ≥3 nuclei. H, The number of osteoclasts under different culture conditions is shown. ACPAs from 3 RA patients were used in conjunction with peripheral blood mononuclear cells from 3 healthy individuals (n = 4 replicates); 10 random images per well were obtained at an original magnification of × 20. * = P < 0.05; ** = P < 0.01; *** = P < 0.001, by Kruskal-Wallis test with Dunn's test for multiple comparisons. Horizontal lines with bars show the mean ± SEM in B and H, and mean ± SD in E. MCSF = macrophage colony-stimulating factor; ns = not significant. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40772/abstract. and observed that AREG promoted the increased migration of FLS, in comparison to controls, in wound-healing assays ( Figures 6A and B) . We confirmed the expression of EGFR on RA FLS, suggesting that the increased invasiveness was likely attributable to increased AREG-induced EGFR signaling ( Figure 6C) .
We also observed that RA FLS proliferated more intensely in the presence of AREG in comparison to control FLS (Figure 6D) . Taken together, our results thus indicate that high levels of AREG in the peripheral blood and synovial fluid of RA patients could be responsible for the aggressive phenotype of FLS in these patients.
Functional synergy between AREG and ACPAs in mediating osteoclastogenesis. The role of AREG in promoting osteolytic activity has been detailed as one of the mediators of bone metastases in breast cancers (45) . Independently, the role of ACPAs in enabling osteoclast differentiation has been described in RA (4) . We thus interrogated the functional synergy between these molecules in mediating osteoclastogenesis. First, we purified ACPAs by binding to a CCP-functionalized column ( Figure 6E ). Next, we evaluated the ability of each of these molecules, either by themselves or in combination, to promote the differentiation of multinucleated tartrate-resistant acid phosphatase-positive osteoclasts from monocyte precursors. Although AREG by itself did not significantly increase the differentiation of osteoclasts, the number of osteoclasts was observed to be higher in cocultures with AREG and ACPAs as compared to all other conditions tested ( Figures 6F-H) . Our findings thus suggest that AREG can synergize with ACPAs in the differentiation of osteoclasts from blood monocytes.
DISCUSSION
The role of RA-CCP POS B cells as a source of autoantibodies contributing to disease pathology in RA has been extensively studied, but the functional programs that help define the biology of the cell have remained elusive. One of the challenges we encountered was the robust and reliable identification of RA-CCP POS B cells, which accounts for <0.1%
of total peripheral B cells in RA patients (14) . We successfully designed a sensitive flow cytometric sorting method using peptide-streptavidin conjugates, and sorted both the IgG POS and IgA POS CCP POS B cells, owing to the fact that the antibody response against citrullinated proteins in RA comprises both IgG-and IgA-type immunoglobulins (46) . Based on the RNA-seq data, we confirmed that the expression of the IL-15Rα protein on the cell surface was enriched in the RA-CCP POS B cell population, and also confirmed that increased levels of sIL-15Rα could be detected within the blood of an independent cohort of CCP-seropositive RA patients. IL- (34) , thereby acting in an autocrine or paracrine manner and influencing cell survival, proliferation, and motility (51) . Previously reported studies are contradictory with regard to AREG concentrations in the blood of RA patients, with evidence of both significantly increased concentrations and no significant differences in comparison to healthy donors (41) (42) (43) . One confounding factor in these reports is CCP seropositivity. Consistent with our studies with RA-CCP POS B cells, our results herein demonstrate significant increases in the concentration of AREG in the blood of CCP-seropositive RA patients in comparison to healthy donors. In parallel, immunohistochemistry has confirmed the expression of both AREG and EGFR within the synovial tissue of RA patients (34, 42) . Investigations using a mouse model of inflammation in RA, in which mice harbored the transgenic IL-6 signal transducer gene, have shown the importance of EGFs, including AREG, in the pathogenesis of arthritis, since targeting AREG either by neutralizing antibodies or by short-hairpin RNA ameliorated the disease severity (43) . The induction of AREG expression is governed by the cytokines transforming growth factor β (TGFβ), TNF, and IL-1β (34, 37) , which are known to be abundant in RA synovial fluid and plasma (52) (results for TGFβ are shown in Supplementary  Figure 10 , http://onlinelibrary.wiley.com/doi/10.1002/art.40772/ abstract). Our data illustrate that AREG can directly promote the proliferation and invasiveness of FLS. As outlined by elegant studies in breast cancer metastasis models, AREG is also known to increase the differentiation and activity of osteoclasts from PBMCs in the presence of RANKL and macrophage colony-stimulating factor (45), both of which are abundantly available in the synovial compartment of RA patients. Our in vitro data further highlight the ability of AREG to act in concert with ACPAs to enhance the differentiation of osteoclasts from blood monocytes. Since our RNA-seq data outlined a role for both IL6ST and IL-6 signaling in RA-CCP POS B cells, this suggests that IL-6 signaling might facilitate AREG up-regulation. Overall, our results indicate that under proinflammatory conditions, all B cells in RA may contribute to the production of AREG irrespective of antigen specificity, which may potentially affect other cells in the joints. Through this study, we are reporting for the first time a comprehensive transcriptome profile of RA-CCP POS B cells in RA. To the best of our knowledge, this is also the first study to conduct whole transcriptome profiling of antigen-specific B cells in any human autoimmune disorder. Our results portray B cells not merely as autoantibody producers, but also as a source of diverse molecules that can influence proliferation, differentiation, and activation of other pathogenic cell types. We anticipate that these data will serve as a foundational data set for investigating multiple hypotheses on the roles of B cells in RA and other autoimmune disorders, and will enable drug discovery and validation based on the biology of RA-CCP POS B cells in RA.
We also recognize that although our report represents an important first step, further studies are required to gain a much deeper understanding of autoreactive B cells in autoimmune biology. Comprehensive studies on the relationships between sIL-15Rα and AREG within the synovial compartment, and all of the different cell types that can secrete these molecules and how they influence the expression and secretion of each other and other signaling cascades, need to be performed. Although direct profiling of synovial B cells can reflect their contribution to RA pathophysiology, obtaining these cells is challenging from a clinical perspective. Arthroscopy is considered an invasive procedure and hence not routinely performed in clinical practice. Similarly, although synovial tissue can be accessed from patients undergoing joint replacement, these patients have end-stage disease not reflective of therapeutically relevant disease. Moreover, although single-cell RNA-seq (scRNA-seq) is better suited for studying moderately or highly expressed transcripts, it would be interesting to perform scRNA-seq to document the heterogeneity in autoimmune B cells, to complement our existing results, especially with synovial B cells.
